Chi-Med starts bookbuilding for $100m Nasdaq IPO
Hutchison China MediTech (Chi-Med), the drug-making arm of Hong Kong billionaire Li Ka-shing’s Hutchison Whampoa, has opened books for its $100m IPO on the Nasdaq.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: